Astellas Pharma Clinical Trials: 912 Led Studies

Archive historyOct 2022 to Jul 2026

146 recorded changes across Astellas Pharma trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 37 of these trials. One is shown below.

Completion date movePrimary completion moved 62 days earlierNCT06440967 · recorded 1 May 2026

Track to read them

+142 more recorded changes · Track a drug to see every change the night it lands

Track pembrolizumab

Most active programmes

The drugs appearing most often across Astellas Pharma's recently active trials. Comparator arms are excluded.

Pembrolizumab11 trials
zolbetuximab9 trials
ipragliflozin8 trials
Oxaliplatin7 trials
Fezolinetant7 trials
Leucovorin5 trials

Upcoming readouts

Next primary completion dates among Astellas Pharma's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Oct 2027A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney DiseasePhase 3
Nov 2027A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-inva…Phase 2
Sept 2028LUCERNA: A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Canc…Phase 3
Jul 2029A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinica…Phase 2
Aug 2029A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX …Phase 3
Mar 2030Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in …Phase 3

Top therapeutic areas

Conditions studied most often across Astellas Pharma's recently active trials.

Type 2 Diabetes Mellitus9 trials
Hot Flashes7 trials
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma5 trials
Urothelial Cancer5 trials
Solid Tumor4 trials
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer4 trials

Astellas Pharma trials

The 50 most significant of Astellas Pharma's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy AdultsNCT07395024Setidegrasib	Phase 1	Locked · track to reveal	OngoingRecruiting	54 est.	31 Jul 2026
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic CancerNCT06396091zolbetuximab	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	12 est.	31 Jul 2026
GRACEA Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During MenopauseNCT07455812Fezolinetant	—	Locked · track to reveal	OngoingActive, not recruiting	105 est.	31 Jul 2026
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerNCT03816163zolbetuximab	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	393 est.	31 Aug 2026
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerNCT06862219Enfortumab Vedotin	Phase 4	Locked · track to reveal	OngoingRecruiting	100 est.	31 Dec 2026
ILUSTROA Study of Zolbetuximab (IMAB362) in Adults With Gastric CancerNCT03505320zolbetuximab	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	143 est.	31 Dec 2026
CANDLELIGHTA Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical PracticeNCT07602530Fezolinetant	—	Locked · track to reveal	OngoingRecruiting	238 est.	28 Feb 2027
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular DegenerationNCT06970665avacincaptad pegol	Phase 4	Locked · track to reveal	OngoingActive, not recruiting	17 est.	30 Jun 2027
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe DiseaseNCT06150820	Na	Locked · track to reveal	OngoingActive, not recruiting	119 est.	30 Jun 2027
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV InjectionNCT06011954Enfortumab Vedotin	—	Not yet scored	OngoingRecruiting	202 est.	31 Jul 2027
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney DiseaseNCT05970172Roxadustat	Phase 3	Locked · track to reveal	OngoingRecruiting	100 est.	30 Oct 2027
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need VentilatorsNCT07052929ASP2957	Phase 1	Locked · track to reveal	OngoingRecruiting	9 est.	31 Oct 2027
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderNCT07475806Enfortumab Vedotin	Phase 2	Locked · track to reveal	OngoingRecruiting	240 est.	30 Nov 2027
EXCELA Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle ConditionNCT06581146	—	Not yet scored	OngoingRecruiting	50 est.	31 Dec 2027
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal CancerNCT07024615ASP2138	Phase 1	Locked · track to reveal	OngoingRecruiting	25 est.	31 Jan 2028
A Study of ASP1002 in Adults for Treatment of Solid TumorsNCT05719558ASP1002	Phase 1	Locked · track to reveal	OngoingRecruiting	210 est.	30 Apr 2028
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerNCT05365581ASP2138	Phase 1	Locked · track to reveal	OngoingRecruiting	398 est.	31 May 2028
EVOLVEA Study to Learn How Stargardt-type Eye Conditions Progress in Children and AdultsNCT07425574	—	Not yet scored	OngoingRecruiting	90 est.	31 Jul 2028
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaNCT05520567Gilteritinib	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	70 est.	31 Jul 2028
LUCERNAA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerNCT06901531zolbetuximab	Phase 3	Locked · track to reveal	OngoingRecruiting	500 est.	30 Sept 2028
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsNCT07094204ASP5834	Phase 1	Locked · track to reveal	OngoingRecruiting	364 est.	30 Nov 2028
A Study of ASP3082 in Adults With Advanced Solid TumorsNCT05382559Setidegrasib	Phase 1	Locked · track to reveal	OngoingRecruiting	681 est.	31 Dec 2028
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate CancerNCT07339267ASP5541	Phase 1	Locked · track to reveal	OngoingRecruiting	12 est.	31 Dec 2028
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate CancerNCT04729114PRL-02 injection	Phase 1	Locked · track to reveal	OngoingRecruiting	174 est.	31 May 2029
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsNCT07287995ASP2998	Phase 1	Locked · track to reveal	OngoingRecruiting	428 est.	30 Jun 2029
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyNCT02960022enzalutamide	Phase 2	Locked · track to reveal	OngoingRecruiting	900 est.	31 Jul 2029
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsNCT07488676ASP546C	Phase 1	Locked · track to reveal	OngoingRecruiting	150 est.	31 Jul 2029
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerNCT07409272Setidegrasib	Phase 3	Locked · track to reveal	OngoingRecruiting	614 est.	31 Aug 2029
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)NCT07140016gilteritinib	Phase 1	Locked · track to reveal	OngoingRecruiting	40 est.	31 Dec 2029
A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a StrokeNCT07318714ASP2246	Phase 1	Locked · track to reveal	OngoingRecruiting	84 est.	28 Feb 2030
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)NCT07566156Enfortumab vedotin	Phase 3	Locked · track to reveal	OngoingRecruiting	390 est.	31 Mar 2030
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationNCT07566052Setidegrasib	Phase 3	Locked · track to reveal	OngoingRecruiting	356 est.	30 Jun 2030
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.NCT06902545zolbetuximab	—	Not yet scored	OngoingRecruiting	377 est.	31 Jul 2030
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic AtrophyNCT06779773Avacincaptad pegol (ACP)	—	Not yet scored	OngoingRecruiting	500 est.	31 Oct 2030
A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)NCT07619105Vesomni	—	Not yet scored	OngoingNot yet recruiting	600 est.	30 Nov 2030
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerNCT07673887ASP2138	Phase 3	Locked · track to reveal	OngoingNot yet recruiting	570 est.	28 Feb 2031
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154ASP5541	Phase 2	Locked · track to reveal	OngoingRecruiting	218 est.	31 May 2032
FORTISGene Transfer Study in Patients With Late Onset Pompe DiseaseNCT04174105zocaglusagene nuzaparvovec	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	11 est.	28 Feb 2035
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyNCT06440967Fezolinetant	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	982 est.	30 Jun 2026
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid TumorsNCT06364696ASP4396	Phase 1	Locked · track to reveal	StoppedTerminated	60 est.	17 Jun 2026
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid ArthritisNCT03971253Peficitinib	—	Not yet scored	Completed	3,000 est.	29 May 2026
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid TumorsNCT05083481ASP1570	Phase 1	Locked · track to reveal	StoppedTerminated	226 est.	11 May 2026
Starlight 3A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through MenopauseNCT06206421Fezolinetant	Phase 3	Locked · track to reveal	Completed	277 est.	19 Mar 2026
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's SyndromeNCT06544642ASP5502	Phase 1	Locked · track to reveal	StoppedTerminated	116 est.	5 Mar 2026
EV-103A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial CancerNCT03288545enfortumab vedotin (EV)	Phase 1	Locked · track to reveal	StoppedTerminated	348 est.	20 Feb 2026
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor OveractivityNCT05621616mirabegron	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	7 est.	16 Feb 2026
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through MenopauseNCT06812754Fezolinetant	Phase 2	Locked · track to reveal	Completed	150 est.	11 Feb 2026
Starlight 2A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through MenopauseNCT06206408Fezolinetant	Phase 3	Locked · track to reveal	Completed	410 est.	22 Oct 2025
A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich AtaxiaNCT06483802ASP2016	Phase 1	Locked · track to reveal	StoppedWithdrawn	0 est.	22 Oct 2025
A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney DiseaseNCT05999747pudexacianinium chloride	Phase 3	Locked · track to reveal	Completed	95 est.	13 Oct 2025

View all trials912

A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults

Phase 1RecruitingNCT07395024 ↗

Primary completion: Jul 2026; estimated
Enrollment: 54; estimated
Start: Feb 2026; Astellas Pharma Global Development, Inc.

Conditions

Healthy Volunteer

Interventions

Setidegrasib
Fluconazole
Carbamazepine
Itraconazole

Brief summary

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with solid tumors have a faulty KRAS gene. One such change in the KRAS gene is called a G12D mutation.…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

Phase 1Active, not recruitingNCT06396091 ↗

Primary completion: Jul 2026; estimated
Enrollment: 12; estimated
Start: Sept 2025; Astellas Pharma Global Development, Inc.

Conditions

Metastatic Pancreatic Adenocarcinoma

Interventions

zolbetuximab
mFOLFIRINOX

Brief summary

Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic cancer. In this study, zolbetuximab…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Dec 2025

Status change · 2

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Phase 2Active, not recruitingNCT03816163 ↗

Primary completion: Aug 2026; estimated
Enrollment: 393; estimated
Start: Mar 2019; Astellas Pharma Global Development, Inc.

Conditions

Pancreatic Cancer
Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma

Interventions

zolbetuximab
nab-paclitaxel
gemcitabine

Brief summary

Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's immune system to attack the tumor.…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Oct 2024

Completion date move · 1

Status change · 1

Enrollment change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4RecruitingNCT06862219 ↗

Primary completion: Dec 2026; estimated
Enrollment: 100; estimated
Start: Jun 2025; Astellas Pharma Global Development, Inc.

Conditions

Metastatic Urothelial Carcinoma

Interventions

Enfortumab Vedotin

Brief summary

This study is for Indian adults in India who have cancer in the bladder lining (urothelial cancer). Their cancer is advanced or has spread to other parts of the body. Enfortumab vedotin is a treatment for this type of cancer. The main aim of the study is to confirm the safety of enfortumab vedotin in Indian adults…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Aug 2025

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

ILUSTRO: A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Phase 2Active, not recruitingNCT03505320 ↗

Primary completion: Dec 2026; estimated
Enrollment: 143; estimated
Start: Jun 2018; Astellas Pharma Global Development, Inc.

Conditions

Pharmacokinetics of Zolbetuximab
Gastric Cancer
Gastro-esophageal Junction (GEJ) Cancer
Pharmacokinetics of Oxaliplatin
Pharmacokinetics of Fluorouracil Bolus (5-FU)

Interventions

zolbetuximab
oxaliplatin
leucovorin
fluorouracil
Pembrolizumab
folinic acid
nivolumab
Docetaxel

Brief summary

Zolbetuximab is being studied as a treatment for people with cancer in and around the stomach or cancer where the food pipe (esophagus) joins the stomach (gastroesophageal junction cancer). Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by…

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 1 Nov 2025

Completion date move · 4

Status change · 3

Enrollment change · 2

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Phase 4Active, not recruitingNCT06970665 ↗

Primary completion: Jun 2027; estimated
Enrollment: 17; estimated
Start: Jul 2025; Astellas Pharma Inc

Conditions

Geographic Atrophy
Age-Related Macular Degeneration

Interventions

avacincaptad pegol

Brief summary

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the light sensitive part at the back of the eye. In AMD, the cells in the macula die over time, usually over several years, leading to vision loss.…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

NaActive, not recruitingNCT06150820 ↗

Primary completion: Jun 2027; estimated
Enrollment: 119; estimated
Start: Feb 2024; Astellas Gene Therapies

Conditions

Pompe Disease (Late-onset)

Interventions

No Intervention

Brief summary

Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body.…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Oct 2025

Status change · 2

Enrollment change · 1

Completion date move · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Phase 3RecruitingNCT05970172 ↗

Primary completion: Oct 2027; estimated
Enrollment: 100; estimated
Start: Jan 2024; Astellas Pharma Global Development, Inc.

Conditions

Chronic Kidney Disease
Renal Anemia

Interventions

Roxadustat

Brief summary

Roxadustat is a licensed medicine to treat anemia in adults with chronic kidney disease (CKD). Anemia is a low level of red blood cells. Current treatment for anemia is to have injections of medicines called erythropoietin stimulating agents (also known as ESAs) to help the bone marrow make more red blood cells. These…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Dec 2025

Completion date move · 1

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

Phase 1RecruitingNCT07052929 ↗

Primary completion: Oct 2027; estimated
Enrollment: 9; estimated
Start: Dec 2025; Astellas Gene Therapies

Conditions

X-Linked Myotubular Myopathy

Interventions

ASP2957
Methylprednisolone
Prednisolone
Sirolimus

Brief summary

X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no approved therapies for XLMTM. The protein myotubularin is needed for muscle development, movement and breathing. A gene called MTM1 tells the body to make myotubularin.…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Nov 2025

Completion date move · 1

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2RecruitingNCT07475806 ↗

Primary completion: Nov 2027; estimated
Enrollment: 240; estimated
Start: Mar 2026; Astellas Pharma Global Development, Inc.

Conditions

Muscle-invasive Bladder Cancer

Interventions

Enfortumab Vedotin
Pembrolizumab

Brief summary

People with a type of bladder cancer called muscle-invasive bladder cancer have cancer that has spread into the muscle wall of the bladder. The standard treatment is to have chemotherapy, followed by surgery to completely remove the bladder. This has a significant impact on people with long-term life-altering changes.…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Phase 1RecruitingNCT07024615 ↗

Primary completion: Jan 2028; estimated
Enrollment: 25; estimated
Start: Oct 2025; Astellas Pharma Global Development, Inc.

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

ASP2138
Oxaliplatin
Leucovorin
5-FU
Irinotecan
Gemcitabine
Nab-paclitaxel
Capecitabine

Brief summary

Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell. The T-cell "tells" the immune system to attack the tumor. This study is for people with resectable…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Mar 2026

Completion date move · 2

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1RecruitingNCT05365581 ↗

Primary completion: May 2028; estimated
Enrollment: 398; estimated
Start: Jun 2022; Astellas Pharma Global Development, Inc.

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction (GEJ) Adenocarcinoma
Pancreatic Adenocarcinoma

Interventions

ASP2138
Pembrolizumab
Oxaliplatin
Leucovorin
Fluorouracil
Ramucirumab
Paclitaxel
Irinotecan

Brief summary

Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This "tells" the immune…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 May 2026

Completion date move · 6

Enrollment change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Phase 1Active, not recruitingNCT05520567 ↗

Primary completion: Jul 2028; estimated
Enrollment: 70; estimated
Start: Jan 2023; Astellas Pharma Global Development, Inc.

Conditions

Acute Myeloid Leukemia (AML)
FLT3-mutated Acute Myeloid Leukemia

Interventions

Gilteritinib
Venetoclax
Azacitidine

Brief summary

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed FLT3 gene. Gilteritinib, given with venetoclax and azacitidine, is…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2026

Status change · 2

Completion date move · 2

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

LUCERNA: A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Phase 3RecruitingNCT06901531 ↗

Primary completion: Sept 2028; estimated
Enrollment: 500; estimated
Start: May 2025; Astellas Pharma Global Development, Inc.

Conditions

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Metastatic Gastric Adenocarcinoma or Cancer
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

zolbetuximab
Pembrolizumab
Capecitabine
Oxaliplatin
Folinic acid (leucovorin or local equivalent)
5-fluorouracil (5-FU)
Placebo

Brief summary

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2026

Completion date move · 1

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Phase 1RecruitingNCT07094204 ↗

Primary completion: Nov 2028; estimated
Enrollment: 364; estimated
Start: Jul 2025; Astellas Pharma Inc

Conditions

Solid Tumor
Non-Small-Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma
Colorectal Cancer

Interventions

ASP5834
panitumumab

Brief summary

Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with solid tumors who…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Sept 2025

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1RecruitingNCT05382559 ↗

Primary completion: Dec 2028; estimated
Enrollment: 681; estimated
Start: Jun 2022; Astellas Pharma Inc

Conditions

Solid Tumor

Interventions

Setidegrasib
Cetuximab
Leucovorin
Oxaliplatin
Fluorouracil
Irinotecan
Nanoparticle albumin-bound-paclitaxel
Gemcitabine

Brief summary

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2 parts. In Part 1,…

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 1 May 2026

Completion date move · 5

Enrollment change · 4

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

Phase 1RecruitingNCT07339267 ↗

Primary completion: Dec 2028; estimated
Enrollment: 12; estimated
Start: Jan 2026; Astellas Pharma Global Development, Inc.

Conditions

Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Metastatic Hormone Sensitive Prostate Cancer

Interventions

ASP5541
Prednisone

Brief summary

In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT). Prednisone is a steroid, and ADT is already given to the men as their standard of care for prostate cancer. The main aims of the study are to check the safety of…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Phase 1RecruitingNCT04729114 ↗

Primary completion: May 2029; estimated
Enrollment: 174; estimated
Start: Jun 2021; Astellas Pharma Global Development, Inc.

Conditions

Prostate Cancer
Metastatic Castration Resistant Prostate Cancer
Metastatic Castration-sensitive Prostate Cancer

Interventions

PRL-02 injection
prednisone
dexamethasone
enzalutamide

Brief summary

Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their cancer has come back…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Oct 2025

Completion date move · 3

Enrollment change · 2

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1RecruitingNCT07287995 ↗

Primary completion: Jun 2029; estimated
Enrollment: 428; estimated
Start: Feb 2026; Astellas Pharma Global Development, Inc.

Conditions

Locally Advanced or Metastatic Malignant Solid Tumors

Interventions

ASP2998
Pembrolizumab
Enfortumab Vedotin
Carboplatin

Brief summary

Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then attack the tumor cells in people with solid tumors. ASP2998 will either be given by itself, or given together with one or…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Feb 2026

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Phase 2RecruitingNCT02960022 ↗

Primary completion: Jul 2029; estimated
Enrollment: 900; estimated
Start: Dec 2016; Astellas Pharma Global Development, Inc.

Conditions

Prostate Cancer

Interventions

enzalutamide
abiraterone acetate
prednisone
Leuprolide acetate

Brief summary

The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Oct 2025

Completion date move · 3

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Phase 1RecruitingNCT07488676 ↗

Primary completion: Jul 2029; estimated
Enrollment: 150; estimated
Start: May 2026; Astellas Pharma Global Development, Inc.

Conditions

Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Pancreatic Adenocarcinoma

Interventions

ASP546C

Brief summary

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both parts of the study, ASP546C will be given…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Phase 3RecruitingNCT07409272 ↗

Primary completion: Aug 2029; estimated
Enrollment: 614; estimated
Start: Feb 2026; Astellas Pharma Global Development, Inc.

Conditions

Pancreatic Cancer
Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma

Interventions

Setidegrasib
Oxaliplatin
Leucovorin
Irinotecan
fluorouracil
liposomal irinotecan
Placebo

Brief summary

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Phase 1RecruitingNCT07140016 ↗

Primary completion: Dec 2029; estimated
Enrollment: 40; estimated
Start: Sept 2025; Astellas Pharma Global Development, Inc.

Conditions

Non-small Cell Lung Cancer (NSCLC)
Anaplastic Lymphoma Kinase (ALK) Positive

Interventions

gilteritinib

Brief summary

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stands for anaplastic lymphoma kinase.…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Oct 2025

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke

Phase 1RecruitingNCT07318714 ↗

Primary completion: Feb 2030; estimated
Enrollment: 84; estimated
Start: Apr 2026; Astellas Pharma Inc

Conditions

Chronic Ischemic Stroke

Interventions

ASP2246
Brain surgery
Sham surgery
Rehabilitation therapy

Brief summary

This study is for adults who have difficulty moving a few months after a stroke. In this study, ASP2246 will be given to people for the first time. This is known as a "first in human" study. The main aims of the study are to check the safety of ASP2246, how well people tolerate it, and to find suitable doses of…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Phase 3RecruitingNCT07566156 ↗

Primary completion: Mar 2030; estimated
Enrollment: 390; estimated
Start: May 2026; Astellas Pharma Global Development, Inc.

Conditions

Urothelial Cancer
Urinary Bladder Neoplasms

Interventions

Enfortumab vedotin
Conventional Radiotherapy
Hypofractionated Radiotherapy
Cisplatin
Fluorouracil
Mitomycin C
Gemcitabine
Pembrolizumab

Brief summary

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

–RecruitingNCT06902545 ↗

Primary completion: Jul 2030; estimated
Enrollment: 377; estimated
Start: Apr 2025; Astellas Pharma Korea, Inc.

Conditions

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Metastatic Gastric Adenocarcinoma or Cancer
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

zolbetuximab

Brief summary

This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Their cancer is locally advanced, unresectable, or metastatic. Locally advanced means the cancer has spread to…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)

–Not yet recruitingNCT07619105 ↗

Primary completion: Nov 2030; estimated
Enrollment: 600; estimated
Start: Sept 2026; Astellas Pharma Korea, Inc.

Conditions

Benign Prostatic Hyperplasia

Interventions

Vesomni

Brief summary

Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control. Men with an enlarged prostate may need to pass urine many times during the day and night which can affect their wellbeing. There…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Phase 3Not yet recruitingNCT07673887 ↗

Primary completion: Feb 2031; estimated
Enrollment: 570; estimated
Start: Jun 2026; Astellas Pharma Global Development, Inc.

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

ASP2138
Pembrolizumab
Oxaliplatin
Capecitabine
Folinic acid
5-FU
Placebo for ASP2138
Placebo for Pembrolizumab

Brief summary

Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a type of immune cell called a T cell. This "tells" the immune system to attack the tumor.…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 15 Jul 2026

New trial · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Phase 2RecruitingNCT07005154 ↗

Primary completion: May 2032; estimated
Enrollment: 218; estimated
Start: Jun 2025; Astellas Pharma Global Development, Inc.

Conditions

Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Metastatic Hormone Sensitive Prostate Cancer

Interventions

ASP5541
Prednisone
Prednisolone
abiraterone acetate
Adrenocorticotropic hormone

Brief summary

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much testosterone is…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Aug 2025

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Phase 3Active, not recruitingNCT06440967 ↗

Primary completion: Jun 2026; estimated
Enrollment: 982; estimated
Start: Jul 2024; Astellas Pharma Global Development, Inc.

Conditions

Hot Flashes

Interventions

Fezolinetant
Placebo
Tamoxifen
Aromatase inhibitor

Brief summary

One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but cannot be given to women on hormone therapy for breast cancer. Fezolinetant, an alternative…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 May 2026

Completion date move · 3

Status change · 2

Enrollment change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Phase 1TerminatedNCT05083481 ↗

Primary completion: May 2026; actual
Enrollment: 226; estimated
Start: Oct 2021; Astellas Pharma Global Development, Inc.

Conditions

Advanced Solid Tumors

Interventions

ASP1570
pembrolizumab
Trifluridine + Tipiracil
Bevacizumab
Docetaxel
Oxaliplatin
Leucovorin
5-Fluorouracil

Brief summary

Immune therapies work with the body's immune system to treat a number of cancers. They work with T-cells, a type of white blood cell, to target and attack specific tumors. However, some tumors can become resistant to attack by T-cells over time. They do this by sending "off" signals to T-cells. The researchers are…

Full record on ClinicalTrials.gov ↗

Change timeline

10 recorded · latest 1 May 2026

Enrollment change · 5

Completion date move · 4

Status change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

Starlight 3: A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

Phase 3CompletedNCT06206421 ↗

Primary completion: Mar 2026; actual
Enrollment: 277; estimated
Start: Feb 2024; Astellas Pharma Inc

Conditions

Hot Flashes

Interventions

Fezolinetant
Placebo

Brief summary

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed. Researchers want to find other ways to treat hot flashes.…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 May 2026

Completion date move · 3

Status change · 2

Enrollment change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

Phase 1TerminatedNCT06544642 ↗

Primary completion: Mar 2026; actual
Enrollment: 116; estimated
Start: Aug 2024; Astellas Pharma Global Development, Inc.

Conditions

Healthy Volunteers
Sjögren's Syndrome

Interventions

ASP5502
Placebo

Brief summary

Primary Sjögren's syndrome (pSS) is a condition when the body's immune system attacks glands that produce fluids, such as the tear and saliva glands. This leads to dry eyes and a dry mouth. However, other symptoms may occur such as fatigue, joint pain, and skin problems. These symptoms can be severe. Symptoms can be…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Apr 2026

Status change · 1

Enrollment change · 1

Completion date move · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

EV-103: A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Phase 1TerminatedNCT03288545 ↗

Primary completion: Feb 2026; actual
Enrollment: 348; estimated
Start: Oct 2017; Astellas Pharma Global Development, Inc.

Conditions

Carcinoma, Transitional Cell
Urinary Bladder Neoplasms
Urologic Neoplasms
Renal Pelvis Neoplasms
Urothelial Cancer
Ureteral Neoplasms
Urethral Neoplasms

Interventions

enfortumab vedotin (EV)
pembrolizumab
cisplatin
carboplatin
gemcitabine

Brief summary

This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder,…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Apr 2026

Completion date move · 4

Status change · 2

Enrollment change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity

Phase 3Active, not recruitingNCT05621616 ↗

Primary completion: Feb 2026; actual
Enrollment: 7; estimated
Start: Feb 2024; Astellas Pharma Global Development, Inc.

Conditions

Neurogenic Detrusor Overactivity

Interventions

mirabegron

Brief summary

People with neurogenic detrusor overactivity (NDO) have poor bladder control because of how their nerves to the bladder are wired. This can cause high pressure in the bladder, causing it to leak urine by accident (incontinence). Mirabegron has already been approved for adults with bladder problems and for children 3…

Full record on ClinicalTrials.gov ↗

Change timeline

11 recorded · latest 1 Apr 2026

Completion date move · 7

Enrollment change · 2

Status change · 2

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

Phase 2CompletedNCT06812754 ↗

Primary completion: Feb 2026; actual
Enrollment: 150; estimated
Start: Mar 2025; Astellas Pharma Global Development, Inc.

Conditions

Hot Flashes

Interventions

Fezolinetant
Placebo

Brief summary

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed. The goal of this study is to confirm if fezolinetant helps reduce…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Apr 2026

Completion date move · 2

Status change · 2

Enrollment change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

Starlight 2: A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause

Phase 3CompletedNCT06206408 ↗

Primary completion: Oct 2025; actual
Enrollment: 410; estimated
Start: Feb 2024; Astellas Pharma Inc

Conditions

Hot Flashes

Interventions

Fezolinetant
Placebo

Brief summary

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jan 2026

Status change · 2

Completion date move · 2

Enrollment change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia

Phase 1WithdrawnNCT06483802 ↗

Primary completion: Oct 2025; actual
Enrollment: 0; estimated
Start: Nov 2024; Astellas Gene Therapies

Conditions

Friedreich Ataxia
Cardiomyopathy

Interventions

ASP2016
Prednisolone

Brief summary

Friedreich Ataxia is a rare condition that causes damage to the nervous system and muscles. People with Friedreich Ataxia have difficulty walking, lose sensation in their arms and legs, and have slurred speech. It can also affect the heart and many people with Friedrich Ataxia develop serious heart problems.…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Dec 2025

Status change · 3

Completion date move · 1

Enrollment change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease

Phase 3CompletedNCT05999747 ↗

Primary completion: Oct 2025; actual
Enrollment: 95; estimated
Start: Mar 2024; Astellas Pharma Global Development, Inc.

Conditions

Intraoperative Ureter Visualization
Abdominolpelvic Surgery

Interventions

pudexacianinium chloride

Brief summary

The ureter is the tube that carries urine from the kidneys to the bladder. It is difficult for surgeons to see the ureter during abdominal surgery. This could lead to injuring the ureter which, although rare, could be serious. This study is about a potential new medical dye, called ASP5354. This dye is injected into…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Dec 2025

Completion date move · 4

Status change · 2

Enrollment change · 1

Track Astellas Pharma drugs to see every change the night it lands.

Track pembrolizumab